LT4072B - Use of a cross-linked polycarboxylic polymer and progesterone for manufacture of medicinal preparations - Google Patents

Use of a cross-linked polycarboxylic polymer and progesterone for manufacture of medicinal preparations Download PDF

Info

Publication number
LT4072B
LT4072B LT96-027A LT96027A LT4072B LT 4072 B LT4072 B LT 4072B LT 96027 A LT96027 A LT 96027A LT 4072 B LT4072 B LT 4072B
Authority
LT
Lithuania
Prior art keywords
progesterone
use according
polymer
medicament
levels
Prior art date
Application number
LT96-027A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT96027A (en
Inventor
William Joseph Bologna
Howard Leslie Levine
Original Assignee
Columbia Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22402302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT4072(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Columbia Lab Inc filed Critical Columbia Lab Inc
Publication of LT96027A publication Critical patent/LT96027A/xx
Publication of LT4072B publication Critical patent/LT4072B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
LT96-027A 1993-09-15 1996-03-11 Use of a cross-linked polycarboxylic polymer and progesterone for manufacture of medicinal preparations LT4072B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/122,371 US5543150A (en) 1993-09-15 1993-09-15 Method of progesterone delivery and affect thereof

Publications (2)

Publication Number Publication Date
LT96027A LT96027A (en) 1996-07-25
LT4072B true LT4072B (en) 1996-11-25

Family

ID=22402302

Family Applications (1)

Application Number Title Priority Date Filing Date
LT96-027A LT4072B (en) 1993-09-15 1996-03-11 Use of a cross-linked polycarboxylic polymer and progesterone for manufacture of medicinal preparations

Country Status (27)

Country Link
US (1) US5543150A (uk)
EP (1) EP0719146B1 (uk)
JP (1) JP3143474B2 (uk)
KR (1) KR100278553B1 (uk)
AT (1) ATE174796T1 (uk)
BR (1) BR9407475A (uk)
CA (1) CA2171939C (uk)
CO (1) CO4290332A1 (uk)
DE (1) DE69415543T2 (uk)
DK (1) DK0719146T3 (uk)
ES (1) ES2126783T3 (uk)
FI (1) FI115444B (uk)
GR (1) GR3029314T3 (uk)
HU (1) HU221583B (uk)
IL (1) IL110972A (uk)
LT (1) LT4072B (uk)
LV (1) LV11527B (uk)
MA (1) MA23329A1 (uk)
MY (1) MY111484A (uk)
NO (1) NO308585B1 (uk)
NZ (1) NZ273816A (uk)
PE (1) PE50795A1 (uk)
PH (1) PH30813A (uk)
RU (1) RU2148393C1 (uk)
UA (1) UA37244C2 (uk)
WO (1) WO1995007699A1 (uk)
ZA (1) ZA947073B (uk)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869081A (en) * 1996-06-28 1999-02-09 The Population Council Progesterone vaginal ring for treatment of infertility
US5985861A (en) * 1996-11-04 1999-11-16 Columbia Laboratories, Inc. Progesterone for treating or reducing ischemia
US6056972A (en) * 1997-02-26 2000-05-02 Dimera, Llc Method for reducing coronary artery reactivity
US6602487B1 (en) 1997-02-26 2003-08-05 Dimera Incorporated Methods and tests for producing and for inhibiting coronary artery vasospasms
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US20040234606A1 (en) * 1997-09-12 2004-11-25 Levine Howard L. Localized vaginal delivery without detrimental blood levels
EP1356806A1 (en) * 1997-09-12 2003-10-29 Columbia Laboratories (Bermuda) Limited A pharmaceutical composition for treating dysmenorrhea and premature labor
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) * 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
JP2001519381A (ja) * 1997-10-10 2001-10-23 インペリアル・カレッジ・イノベイションズ・リミテッド 子宮収縮管理のためのｃｓａｉｄｔｍ化合物の使用
US6306914B1 (en) * 1997-10-21 2001-10-23 Columbia Laboratories, Inc. Progestin therapy for maintaining amenorrhea
AU4406899A (en) * 1998-05-20 1999-12-06 Bent Formby Progesterone treatment of cancer
US20070178139A1 (en) * 1998-11-18 2007-08-02 Yankov Vladimir I Vaginally administratable progesterone-containing tablets and method for preparing same
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
US6479045B2 (en) 1999-12-22 2002-11-12 Columbia Laboratories, Inc. Vaginal pH buffering for preventing miscarriage and premature labor, by treating or preventing bacterial vaginosis
US6544553B1 (en) 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
GB0009914D0 (en) 2000-04-20 2000-06-07 Metris Therapeutics Limited Device
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
PT1363600E (pt) * 2001-02-15 2008-12-22 Access Pharma Inc Formulações líquidas para a prevenção e para o tratamento de doenças e distúrbios das mucosas
US20060073174A1 (en) * 2001-08-16 2006-04-06 Access Pharmaceuticals, Inc. Adherent and erodible film to treat a moist surface of a body tissue
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US20030114394A1 (en) * 2001-10-29 2003-06-19 Levine Howard L. Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US7709026B2 (en) 2001-10-29 2010-05-04 Columbia Laboratories, Inc. Low concentration of peroxide for treating or preventing vaginal infections
US8425892B2 (en) 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
US20080182841A1 (en) * 2001-10-29 2008-07-31 Levine Howard L Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US7572780B2 (en) 2003-01-21 2009-08-11 Dimera, Incorporated Method and kit for reducing the symptoms of peripheral vascular disease
DE602004026173D1 (de) * 2003-04-29 2010-05-06 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
ES2237298B1 (es) 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
CN1845723B (zh) * 2003-09-03 2010-07-21 迷斯康贸易有限公司 子宫内膜异位症的治疗方法
CA2537702C (en) 2003-09-03 2012-01-03 Miscon Trading S.A. Methods for the treatment of endometriosis
EP1898880A2 (en) * 2005-06-16 2008-03-19 Warner Chilcott Company Inc. Gel compositions for topical administration
US10016442B2 (en) * 2005-06-16 2018-07-10 Allergan Pharmaceuticals International Limited Estrogen compositions for vaginal administration
CA2654152A1 (en) * 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
ES2310968B1 (es) 2007-06-25 2010-02-08 Italfarmaco, S.A. Uso de estriol en bajas dosis.
KR20100065190A (ko) * 2007-09-14 2010-06-15 닛토덴코 가부시키가이샤 약물 담체
US12011423B2 (en) 2007-11-06 2024-06-18 Foraviset Ltd. S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders
GB0723882D0 (en) * 2007-12-07 2008-01-23 Univ Leicester Methods for the detection of a threatened miscarriage
CA3016642A1 (en) 2008-02-04 2009-08-13 Ferring B.V. Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
US9107696B2 (en) 2008-08-06 2015-08-18 Emory University Method of embryo transfer that eliminates transferred air while hormonally inducing implantation and apparatus
ES2344673B1 (es) 2008-08-07 2011-05-03 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
US8421747B2 (en) 2008-09-24 2013-04-16 Microsoft Corporation Object detection and user settings
ES2344675B1 (es) 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
CA2793712A1 (en) * 2010-03-22 2011-09-29 Repros Therapeutics Inc. Compositions and methods for non-toxic delivery of antiprogestins
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US8435972B2 (en) 2010-09-02 2013-05-07 Emory University Method for the treatment of central nervous system cancers and compositions related thereto
EP2731587A1 (en) * 2011-07-15 2014-05-21 Universiteit Gent Intravaginal delivery system
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
LT2782584T (lt) 2011-11-23 2021-09-10 Therapeuticsmd, Inc. Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2861346C (en) * 2012-01-26 2020-04-07 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
MX363640B (es) 2012-05-31 2019-03-28 Repros Therapeutics Inc Formulaciones y metodos para la administracion vaginal de antiprogestinas.
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
EP2914268B1 (en) 2012-11-02 2018-07-04 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
CN103239389A (zh) * 2013-06-03 2013-08-14 南京泽恒医药技术开发有限公司 一种治疗先兆性流产的黄体酮缓释凝胶的制备方法
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
US20170035781A1 (en) 2015-06-22 2017-02-09 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20200019735A (ko) * 2017-06-22 2020-02-24 비라말 리미티드 약물 전달을 위한 조성물 및 그의 사용 방법
ES2948955T3 (es) 2018-11-30 2023-09-22 Viramal Ltd Un método de preparación de un agente gelificante, el agente gelificante obtenido de este modo y el uso de dicho agente gelificante
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4615697A (en) 1983-11-14 1986-10-07 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
US7863879B2 (en) 2007-06-04 2011-01-04 Holtek Semiconductor Inc. AC signal producer and method thereof
US7862282B2 (en) 2008-07-24 2011-01-04 Autoliv Asp, Inc. Separation fastener with segmented washer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3588620A (en) * 1969-08-06 1971-06-28 Gen Electric Electrical control device panel assembly with multifunctional insulating support means
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
US4916574A (en) * 1989-06-06 1990-04-10 Siemens Energy & Automation, Inc. Panelboard bus bar arrangement
DE69014081T2 (de) * 1989-10-31 1995-03-30 Columbia Laboratories, Inc., Miami, Fla. Mittel zur Feuchthaltung vaginalen Gewebes.
EP0599888A1 (de) * 1991-08-05 1994-06-08 Trawöger, Werner Mittel gegen beläge an benetzten oberflächen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4615697A (en) 1983-11-14 1986-10-07 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
US7863879B2 (en) 2007-06-04 2011-01-04 Holtek Semiconductor Inc. AC signal producer and method thereof
US7862282B2 (en) 2008-07-24 2011-01-04 Autoliv Asp, Inc. Separation fastener with segmented washer

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ADLERCREUTZ H, MARTIN F.: "Biliary excretion and intestinal metabolism of progesterone and estrogens in man", J STEROID BIOCHEM., 1980, pages 231 - 244, XP023415930, DOI: doi:10.1016/0022-4731(80)90196-X
CROXATTO HB ET AL.: "Plasma progesterone levels following subdermal implantation of progesterone pellets in lactating women", ACTA ENDOCRINOL (COPENH)., 1982, pages 630
M. WHITEHEAD, V. GODFREE: "Hormone Replacement Therapy", pages: 91
MAUVAIS-JARVIS P, BAUDOT N, BERCOVICI JP.: "In vivo studies on progesterone metabolism by human skin.", J CLIN ENDOCRINOL METAB., 1969, pages 1580 - 1585
MAXSON WS, HARGROVE JT.: "Bioavailability of oral micronized progesterone", FERTIL STERIL., 1985, pages 622 - 626
MAXSON WS: "The use of progesterone in the treatment of PMS", CLIN OBSTET GYNECOL, 1987, pages 465 - 477
NILLIUS SJ, JOHANSSON ED.: "Plasma levels of progesterone after vaginal, rectal, or intramuscular administration of progesterone", AM J OBSTET GYNECOL., 1971, pages 470 - 477
SITRUK-WARE LR ET AL.: "Inadequate corpus luteal function in women with benign breast diseases", J CLIN ENDOCRINOL METAB., 1977, pages 771 - 774
SITRUK-WARE R: "Oral micronized progesterone. Bioavailability pharmacokinetics, pharmacological and therapeutic implications--a review", CONTRACEPTION, 1987, pages 373 - 402, XP023167138, DOI: doi:10.1016/0010-7824(87)90088-6
VILLANUEVA B, CASPER RF, YEN SS.: "Intravaginal administration of progesterone: enhanced absorption after estrogen treatment", FERTIL STERIL., 1981, pages 433 - 437

Also Published As

Publication number Publication date
LV11527B (en) 1997-02-20
EP0719146A1 (en) 1996-07-03
JP3143474B2 (ja) 2001-03-07
HUT76824A (en) 1997-11-28
HU9600669D0 (en) 1996-05-28
ATE174796T1 (de) 1999-01-15
PE50795A1 (es) 1996-01-19
NO961044D0 (no) 1996-03-14
EP0719146B1 (en) 1998-12-23
GR3029314T3 (en) 1999-05-28
CO4290332A1 (es) 1996-04-17
ZA947073B (en) 1995-05-02
DE69415543T2 (de) 1999-06-17
HU221583B (hu) 2002-11-28
KR100278553B1 (ko) 2001-01-15
FI961221A (fi) 1996-05-14
CA2171939A1 (en) 1995-03-23
MA23329A1 (fr) 1995-04-01
RU2148393C1 (ru) 2000-05-10
NZ273816A (en) 2007-09-28
NO961044L (no) 1996-05-14
DK0719146T3 (da) 1999-08-23
US5543150A (en) 1996-08-06
IL110972A (en) 1998-03-10
PH30813A (en) 1997-10-17
BR9407475A (pt) 1996-11-12
AU7726194A (en) 1995-04-03
LT96027A (en) 1996-07-25
NO308585B1 (no) 2000-10-02
ES2126783T3 (es) 1999-04-01
FI961221A0 (fi) 1996-03-15
FI115444B (fi) 2005-05-13
DE69415543D1 (de) 1999-02-04
WO1995007699A1 (en) 1995-03-23
MY111484A (en) 2000-06-30
UA37244C2 (uk) 2001-05-15
JPH09502724A (ja) 1997-03-18
LV11527A (lv) 1996-10-20
IL110972A0 (en) 1994-11-28
CA2171939C (en) 2002-01-01
AU689133B2 (en) 1998-03-26

Similar Documents

Publication Publication Date Title
LT4072B (en) Use of a cross-linked polycarboxylic polymer and progesterone for manufacture of medicinal preparations
RU2330667C2 (ru) Прогестинотерапия с регулируемым кровотечением
RU2110274C1 (ru) Способ лечения состояния, зависящего от эстрогенов яичников
STUMPF Pharmacokinetics of estrogen
KR100370908B1 (ko) 기능부전성자궁출혈치료용약제의제조에유용한프로게스테론길항제
Gupta et al. Effect of mifepristone on dilatation of the pregnant and non-pregnant cervix
BG62383B1 (bg) Метод за хормонзаместващо лечение
KR20020035879A (ko) 자궁내막 조직의 자궁외 증식, 만성 골반 동통 및 난관폐쇄의 치료적 관리 방법
JP2023508606A (ja) 排卵を誘発し、黄体期支持を提供するプロゲステロン製剤
Bergqvist Current drug therapy recommendations for the treatment of endometriosis
BG65817B1 (bg) Мезопрогестини (прогестерон рецептор модулатори) за лечение и профилактика на хормонозависими доброкачествени гинекологични заболявания
JP2021522227A (ja) １つ以上のエストロゲン関連疾患を処置するための組成物
AU689133C (en) Novel method of progesterone delivery and affect thereof
Ratnam et al. New approaches to female fertility regulation—an overview
Ng et al. The use of hormonal intrauterine systems in menopausal women
UA79421C2 (en) Progestin therapy with regular menstrual bleeding

Legal Events

Date Code Title Description
TH9A Changes in patent title/claims

Free format text: 4. PANAUDOJIMAS PAGAL 1 PUNKTA, B E S I S K I R I A N T I S TUO, KAD VAISTAS SKIRTAS PAGERINTI GIMDOS GLEIVINES SEKRECIJOS PASIKEITIMA.

PC9A Transfer of patents

Free format text: COLUMBIA LABORATORIES (BERMUDA) LIMITED,ROSEBANK CENTER 14, BERMUDIANA ROAD, PEMBROKE HM08,BM,990816

MK9A Expiry of a patent

Effective date: 20140913